US FDA Clears Additional Bio-Rad Blood Typing Products.
M2 PHARMA-January 25, 2018-US FDA Clears Additional Bio-Rad Blood Typing Products
(C)2018 M2 COMMUNICATIONS
- Hercules, California-based life science research and clinical diagnostic products provider Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) has received 510(k) clearance from the US Food and Drug Administration for the IH-Incubator L and IH-Centrifuge L instruments to be used with the full range of Bio-Rad's IH-System Gel Reagents for manual blood typing methods, the company said.
With the addition of the IH-Centrifuge L and IH-Incubator L to Bio-Rad's portfolio of blood typing platforms, transfusion medicine laboratories of any size can standardise automated and manual typing with one method and supplier.
The unique design of the two instruments maximizes efficiency and space in the laboratory by accommodating both conventional tube and gel blood typing.
Bio-Rad provides a wide variety of platforms, reagents, data management, and connectivity solutions to address different blood typing needs, offering efficient and reliable results for blood grouping, phenotyping, crossmatching, antibody screening and identification, direct antiglobulin tests, and single antigen typing.
Bio-Rad Laboratories develops, manufactures, and markets a broad range of innovative products and solutions for the life science research and clinical diagnostic markets. Its products advance the discovery process and improve healthcare.
Its customers are university and research institutions, hospitals, public health and commercial laboratories, biotechnology, pharmaceutical, as well as applied research laboratories that include food safety and environmental quality testing.
The company has a global network of operations with more than 8,000 employees worldwide.
((Comments on this story may be sent to firstname.lastname@example.org))
|Printer friendly Cite/link Email Feedback|
|Date:||Jan 25, 2018|
|Previous Article:||USPTO Issues Syros Two Patents Covering Methods for Stratifying Patients for Treatment with Its Selective RARI[+ or -] Agonist.|
|Next Article:||Speciality European Pharma to Rebrand as Contura in Order to Consolidate its Corporate Structure and Drive Growth.|